NL-OMON22637已完成不适用
Randomized phase II/III study of Risedronate in combination with Docetaxel versus Docetaxel alone in patients with hormone refractory prostate cancer.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 480
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically proven prostate adenocarcinoma;
- •2. Hormone refractory;
排除标准
- •1. Previous or concomitant use of biphosphonates;
- •2. Prior chemotherapy or radiotherapy within 4 weeks prior to treatment start;
研究者
相似试验
已完成
不适用
Randomized phase II/III study of Risedronate in combination with Docetaxel versus Docetaxel alone in patients with hormone refractory prostate cancerMalignant neoplasm of prostateProstate CancerCancerISRCTN22844568Erasmus Medical Centre (Netherlands)480
已完成
2 期
Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot StudyAnkylosing SpondylitisNCT01038011University of Zurich
已完成
4 期
SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.Colles' FractureNCT00460733Sanofi141
已完成
不适用
Study on preventive effect of risedronate administration on aromatase inhibitor-induced bone mineral loss in the endoclinical therapy for postmenopausal breast cancer patientsHormone-receptor positive, postmenopausal primary breast cancerJPRN-UMIN000004375Graduate School of Medicine Kyoto University64
已完成
4 期
Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With OsteoporosisOsteoporosisNCT01675297Hanlim Pharm. Co., Ltd.1,053